Brofaromine: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 33: | Line 33: | ||
[[Category:Antidepressants]] | [[Category:Antidepressants]] | ||
[[Category:Monoamine oxidase inhibitors]] | [[Category:Monoamine oxidase inhibitors]] | ||
<gallery> | |||
File:Brofaromine.svg|Brofaromine | |||
</gallery> | |||
Latest revision as of 00:50, 20 February 2025
Overview of the antidepressant drug Brofaromine
| Brofaromine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA) that was developed as an antidepressant and anxiolytic agent. It belongs to the class of monoamine oxidase inhibitors (MAOIs), which are used to treat depression by increasing the levels of neurotransmitters in the brain.
Mechanism of Action[edit]
Brofaromine works by selectively inhibiting the enzyme monoamine oxidase A (MAO-A). This enzyme is responsible for breaking down monoamines such as serotonin, norepinephrine, and dopamine. By inhibiting MAO-A, brofaromine increases the availability of these neurotransmitters, which can help alleviate symptoms of depression and anxiety.
Pharmacokinetics[edit]
Brofaromine is absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism. It has a relatively short half-life, which allows for reversible inhibition of MAO-A, reducing the risk of hypertensive crisis associated with traditional MAOIs.
Clinical Use[edit]
Brofaromine was investigated for the treatment of major depressive disorder and anxiety disorders. However, it was never marketed due to the development of newer antidepressants with more favorable side effect profiles.
Side Effects[edit]
Common side effects of brofaromine include nausea, headache, and insomnia. Unlike traditional MAOIs, brofaromine has a lower risk of causing tyramine-induced hypertensive crisis, allowing for a less restrictive diet.
Development and History[edit]
Brofaromine was developed in the 1980s and underwent clinical trials to assess its efficacy and safety. Despite promising results, it was not brought to market, partly due to the emergence of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants that offered similar benefits with fewer dietary restrictions and side effects.
Related pages[edit]
-
Brofaromine
